切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (03) : 151 -154. doi: 10.3877/cma.j.issn.1674-0807.2016.03.006

论著

赖氨酰氧化酶样蛋白2 及E-钙黏蛋白在三阴性乳腺癌中的表达及临床意义
孙吉瑞1, 张金库1,†(), 周炳娟1, 乔海芝1, 陈红1, 马秋双1, 陈雪1   
  1. 1.071000 保定市第一中心医院病理科
  • 收稿日期:2015-01-04 出版日期:2016-06-01
  • 通信作者: 张金库

Expressions of lysyl oxidase-like protein 2 and E-cadherin in triple-negative breast cancer and clinical significance

Jirui Sun1, Jinku Zhang1,†(), Bingjuan Zhou1, Haizhi Qiao1, Hong Chen1, Qiushuang Ma1, Xue Chen1   

  1. 1.Department of Pathology, First Central Hospital of Baoding City, Baoding 071000, China
  • Received:2015-01-04 Published:2016-06-01
  • Corresponding author: Jinku Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙吉瑞, 张金库, 周炳娟, 乔海芝, 陈红, 马秋双, 陈雪. 赖氨酰氧化酶样蛋白2 及E-钙黏蛋白在三阴性乳腺癌中的表达及临床意义[J/OL]. 中华乳腺病杂志(电子版), 2016, 10(03): 151-154.

Jirui Sun, Jinku Zhang, Bingjuan Zhou, Haizhi Qiao, Hong Chen, Qiushuang Ma, Xue Chen. Expressions of lysyl oxidase-like protein 2 and E-cadherin in triple-negative breast cancer and clinical significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(03): 151-154.

目的

探讨赖氨酰氧化酶样蛋白2(LOXL2)、E-钙黏蛋白(E-cadherin)在三阴性乳腺癌(TNBC)中的表达及相互关系。

方法

收集2008 年8 月至2014 年3 月在保定市第一中心医院治疗的浸润性乳腺癌患者的组织标本进行回顾性分析,包括TNBC 66 例及其癌旁正常乳腺组织,非TNBC(non-TNBC)70 例。 采用免疫组织化学方法检测3 组中LOXL2 及E-cadherin 的表达。 LOXL2 和E-cadherin 的表达及其与TNBC 患者临床病理因素的关系采用χ2 检验,LOXL2 和E-cadherin 相关性分析采用Spearman 等级相关性分析。

结果

LOXL2 在TNBC 组、non-TNBC 组和正常乳腺组织中的阳性表达率分别为74.2%(49/66)、51.4%(36/70)和21.2%(14/66), 差异有统计学意义(χ2=37.387,P＜0.001)。 TNBC 组的LOXL2 阳性表达率高于non-TNBC 组及正常乳腺组织(χ2=7.544、37.198, P 均＜0.017)。 E-cadherin 在TNBC、non-TNBC 及癌旁正常乳腺组织中的阳性表达率分别为24.2%(16/66)、41.4%(29/70)和97.0%(64/66), 差异有统计学意义(χ2=77.031,P＜.001)。 TNBC 组的E-cadherin阳性表达率低于正常乳腺组织(χ2=73.108,P＜.017), 但是与non-TNBC 组比较,差异无统计学意义(χ2=4.532,P＞0.017)。 在TNBC 患者中,LOXL2 和E-cadherin 的表达与淋巴结转移(χ2 =11.509、9.964, P=0.001、0.003)及临床分期(χ2 =7.436、9.175, P=0.006、0.002)有关,与患者的年龄(χ2 =0.169、0.539, P=0.681、0.463)和肿瘤直径(χ2 =1.418、0.592, P=0.492、0.744)无关。 LOXL2 与E-cadherin 蛋白在TNBC 中的表达呈负相关(r=-0.475,P＜0.001)。

结论

LOXL2 可能成为新的判断TNBC 预后的分子标志物。

关键词: 乳腺肿瘤, 受体, erbB-2, 钙粘着糖蛋白类

Objective

To investigate the expressions of lysyl oxidase-like protein 2 (LOXL2) and E-cadherin in triple-negative breast cancer (TNBC) and their correlation.

Methods

The tissue samples from invasive breast cancer patients treated in First Central Hospital of Baoding City from August 2008 to March 2014 were collected for retrospective analysis, including 66 cases of TNBC and their normal breast tissue as control, 70 cases of non-TNBC. Immunohistochemistry was used to detect the expressions of LOXL2 and E-cadherin in samples. The expressions of LOXL2 and E-cadherin and their relationship with clinicopathological parameters were compared using χ2 test, and the correlation of LOXL2 and E-cadherin was analyzed using Spearman correlation analysis.

Results

The positive rate of LOXL2 was 74.2% (49/66) in TNBC group,51.4% (36/70) in non-TNBC group and 21.2% (14/66) in control group, which indicated a significant difference (χ2=37.387,P＜.001). LOXL2 positive rate in TNBC group was significantly higher than that in non-TNBC group or in normal breast tissue (χ2= 7.544,37.198, bothP＜0.017). The positive rate of E-cadherin was 24.2% (16/66) in TNBC group, 41.4% (29/70) in non-TNBC group and 97.0%(64/66) in control group, which indicated a significant difference (χ2 =77.031, P＜0.001). E-cadherin positive rate in TNBC group was significantly lower than that in normal breast tissue (χ2 = 73.108, P＜0.017), but there was no significant difference between TNBC group and non-TNBC group (χ2= 4.532, P＞0.017). In TNBC patients, the expressions of LOXL2 and E-cadherin were correlated with lymph node metastasis (χ2 =11.509, 9.964; P=0.001, 0.003) and TNM staging (χ2 =7.436, 9.175; P=0.006,0.002), but they were not correlated with the patients'age (χ2=0.169,0.539; P=0.681, 0.463) and tumor diameter (χ2=1.418,0.592; P=0.492,0.744). LOXL2 was negatively correlated with E-cadherin in TNBC samples (r=- 0.475,P＜0.001).

Conclusion

LOXL2 may have the potential to be a molecular marker for the prognosis of TNBC patients.

Key words: Breast neoplasms, Receptor, erbB-2, Cadherins
图1 LOXL2 及E-cadherin 在三阴性乳腺癌中的表达(MaxVision ×100) 注:图a 所示LOXL2 在细胞质呈阳性表达;图b 所示E-cadherin 在细胞膜呈阳性表达;LOXL2 为赖氨酰氧化酶样蛋白2;E-cadherin 为E-钙黏蛋白
表1 各组中LOXL2 和E-cadherin 的表达[例(%)]
组别 例数 LOXL2 E-cadherin
阳性 阴性 阳性 阴性
TNBC 66 49(74.2) 17(25.8) 16(24.2) 50(75.8)
non-TNBC 70 36(51.4) 34(48.6) 29(41.4)a 41(58.6)
正常乳腺组织 66 14(21.2) 52(78.8) 64(97.0) 2(3.0)
χ2值 37.387 77.031
P值 ＞0.001 ＞0.001
表2 三阴性乳腺癌的临床病理特征与LOXL2、E-cadherin 表达的关系
临床病理特征 例数 LOXL2(例) χ2值 P值 E-cadherin(例) χ2值 P值
阳性 阴性 阳性 阴性
年龄(岁)
＜48 30 23 7 0.169 0.681 6 24 0.539 0.463
≥48 36 26 10 10 26
肿瘤直径
≤2 cm 40 29 11 1.418 0.492 9 31 0.191 0.909
＞2 cm及＜5 cm 18 15 3 5 13
≥5 cm 8 5 3 2 6
临床分期
Ⅰ、Ⅱ 28 16 12 7.436 0.006 12 16 9.175 0.002
Ⅲ 38 33 5 4 34
淋巴结转移
有 35 32 3 11.509 0.001 3 32 9.964 0.003
无 31 17 14 13 18
表3 LOXL2 和E-cadherin 在三阴性乳腺癌中表达的相关性(例)
E-cadherin LOXL2 合计
阳性 阴性
阳性 6 10 16
阴性 43 7 50
合计 49 17 66
[1]
Jemal A, Bray F,Center MM. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
[2]
胡夕春,王碧芸,邵志敏,等.2011 年《St.Gallen 早期乳腺癌初始治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J/CD].中华乳腺病杂志:电子版,2011,5(4):404-407.
[3]
Cano A, Santamaría PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor progression[J]. Future Oncol, 2012, 8(9):1095-1108.
[4]
Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells [J]. Semin Cancer Biol, 2012, 22(3):194-207.
[5]
Jiang J, Tang YL,Liang XH. EMT:a new vision of hypoxia promoting cancer progression [J]. Cancer Biol Ther,2011,11(8):714-723.
[6]
Kerosuo L, Bronner-Fraser M. What is bad in cancer is good in the embryo: importance of EMT in neural crest development [J]. Semin Cell Dev Biol,2012,23(3):320-332.
[7]
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A,2001,98(19):10869-10874.
[8]
Moreno-Bueno G, Salvador F, Martín A, et al. Lysyl oxidase-like 2(LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas [J]. EMBO Mol Med,2011,3(9):528-544.
[9]
李伟,熊正文,李宏伟,等. Cox-2、E-cad 的mRNA 及蛋白在乳腺浸润性导管癌中的表达及意义[J]. 解放军医药杂志, 2011,23(4):9-12.
[10]
Zhan P,Shen XK,Qian Q,et al. Down-regulation of lysyl oxidase-like 2(LOXL2) is associated with disease progression in lung adenocarcinomas[J]. Med Oncol,2012,29(2):648-655.
[11]
Kim YJ, Kang HB, Yim HS, et al. NDRG2 positively regulates E-cadherin expression and prolongs overall survival in colon cancer patients[J]. Oncol Rep,2013,30(4):1890-1898.
[12]
孙淑明,卢晓峰,吴丽娥,等. E-钙粘蛋白在胃癌浸润、转移中的作用[J].汕头大学医学院学报,2008,21(3):146-148.
[13]
Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Association of E-cadherin and β-catenin immunoexpression with clinicopathologic feathers in primary ovarian carcinomas [J]. Hum Pathol,2004,35(6):663-669.
[14]
Li W, Nellaiappan K,Strassmaier T,et al. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells [J]. Proc Natl Acad Sci U S A,1997,94(24):12817-12822.
[15]
Jourdan-Le Saux C, Tronecker H, Bogic L, et al. The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues [J]. J Biol Chem,1999,274 (18):12939-12944.
[16]
Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo[J]. Cancer Res,2003,63(7):1657-1666.
[17]
黄菁. 赖氨酰氧化酶样蛋白-2 在乳腺癌诊断中的应用价值[J].现代预防医学,2012,39(21):5631-5633.
[18]
Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression [J]. EMBO J,2005,24(19):3446-3458.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号